121 related articles for article (PubMed ID: 30482142)
1. Regulation of Tumor Suppressor Gene CDKN2A and Encoded p16-INK4a Protein by Covalent Modifications.
Jiao Y; Feng Y; Wang X
Biochemistry (Mosc); 2018 Nov; 83(11):1289-1298. PubMed ID: 30482142
[TBL] [Abstract][Full Text] [Related]
2. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
Ramsey MR; Krishnamurthy J; Pei XH; Torrice C; Lin W; Carrasco DR; Ligon KL; Xiong Y; Sharpless NE
Cancer Res; 2007 May; 67(10):4732-41. PubMed ID: 17510401
[TBL] [Abstract][Full Text] [Related]
3. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
McKenzie HA; Fung C; Becker TM; Irvine M; Mann GJ; Kefford RF; Rizos H
Hum Mutat; 2010 Jun; 31(6):692-701. PubMed ID: 20340136
[TBL] [Abstract][Full Text] [Related]
4. C-terminal domain of p16(INK4a) is adequate in inducing cell cycle arrest, growth inhibition and CDK4/6 interaction similar to the full length protein in HT-1080 fibrosarcoma cells.
Fahham N; Sardari S; Ostad SN; Vaziri B; Ghahremani MH
J Cell Biochem; 2010 Dec; 111(6):1598-606. PubMed ID: 21053367
[TBL] [Abstract][Full Text] [Related]
5. The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments.
Witkiewicz AK; Knudsen KE; Dicker AP; Knudsen ES
Cell Cycle; 2011 Aug; 10(15):2497-503. PubMed ID: 21775818
[TBL] [Abstract][Full Text] [Related]
6. Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer.
Zhao R; Choi BY; Lee MH; Bode AM; Dong Z
EBioMedicine; 2016 Jun; 8():30-39. PubMed ID: 27428416
[TBL] [Abstract][Full Text] [Related]
7. p16INK4a-induced senescence is disabled by melanoma-associated mutations.
Haferkamp S; Becker TM; Scurr LL; Kefford RF; Rizos H
Aging Cell; 2008 Oct; 7(5):733-45. PubMed ID: 18843795
[TBL] [Abstract][Full Text] [Related]
8. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
9. CDK4 and CDK6 delay senescence by kinase-dependent and p16INK4a-independent mechanisms.
Ruas M; Gregory F; Jones R; Poolman R; Starborg M; Rowe J; Brookes S; Peters G
Mol Cell Biol; 2007 Jun; 27(12):4273-82. PubMed ID: 17420273
[TBL] [Abstract][Full Text] [Related]
10. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of CDKN2A methylation, mRNA, and p16(INK4a) protein expression in children and adolescents with Burkitt lymphoma: biological and clinical implications.
Robaina MC; Faccion RS; Arruda VO; de Rezende LM; Vasconcelos GM; Apa AG; Bacchi CE; Klumb CE
Leuk Res; 2015 Feb; 39(2):248-56. PubMed ID: 25542698
[TBL] [Abstract][Full Text] [Related]
12. Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas.
Kirsch M; Mörz M; Pinzer T; Schackert HK; Schackert G
Genes Chromosomes Cancer; 2009 Feb; 48(2):143-54. PubMed ID: 18973139
[TBL] [Abstract][Full Text] [Related]
13. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
14. Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines.
McLaughlin-Drubin ME; Park D; Munger K
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16175-80. PubMed ID: 24046371
[TBL] [Abstract][Full Text] [Related]
15. Direct modulation of rheumatoid inflammatory mediator expression in retinoblastoma protein-dependent and -independent pathways by cyclin-dependent kinase 4/6.
Nonomura Y; Nagasaka K; Hagiyama H; Sekine C; Nanki T; Tamamori-Adachi M; Miyasaka N; Kohsaka H
Arthritis Rheum; 2006 Jul; 54(7):2074-83. PubMed ID: 16802342
[TBL] [Abstract][Full Text] [Related]
16. The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements.
D'Amico M; Wu K; Fu M; Rao M; Albanese C; Russell RG; Lian H; Bregman D; White MA; Pestell RG
Cancer Res; 2004 Jun; 64(12):4122-30. PubMed ID: 15205322
[TBL] [Abstract][Full Text] [Related]
17. Alterations of the INK4a-ARF gene locus in pleomorphic adenoma of the parotid gland.
Weber A; Langhanki L; Schütz A; Wittekind C; Bootz F; Tannapfel A
J Pathol; 2002 Nov; 198(3):326-34. PubMed ID: 12375265
[TBL] [Abstract][Full Text] [Related]
18. The atr protein kinase controls UV-dependent upregulation of p16INK4A through inhibition of Skp2-related polyubiquitination/degradation.
Al-Khalaf HH; Hendrayani SF; Aboussekhra A
Mol Cancer Res; 2011 Mar; 9(3):311-9. PubMed ID: 21270107
[TBL] [Abstract][Full Text] [Related]
19. The tumour suppressor CDKN2A/p16
Wouters K; Deleye Y; Hannou SA; Vanhoutte J; Maréchal X; Coisne A; Tagzirt M; Derudas B; Bouchaert E; Duhem C; Vallez E; Schalkwijk CG; Pattou F; Montaigne D; Staels B; Paumelle R
Diab Vasc Dis Res; 2017 Nov; 14(6):516-524. PubMed ID: 28868898
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Megakaryopoiesis and Platelet Activity in Hypercholesterolemic, B6-Ldlr-/-, Cdkn2a-Deficient Mice.
Wang W; Oh S; Koester M; Abramowicz S; Wang N; Tall AR; Welch CL
Circ Cardiovasc Genet; 2016 Jun; 9(3):213-22. PubMed ID: 27098250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
